|
|
|
|
|
|
by Vinnl
2656 days ago
|
|
|
There's an interesting Dutch article from January about how the rights ended up with this company [1]. It doesn't say anything about patents, but it does say (my translation): > The producer (AAA, later bought by Novartis) gets exclusive rights to sell the drug, for ten years in the EU, and for seven in the US. The only exception is hospital pharmacies preparing the drug for their own patients. [1] https://nos.nl/artikel/2266712-hoe-nederlands-kankeronderzoe... |
|
|